Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 11/14/22
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime PatentGlobeNewsWire • 10/25/22
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart FailureGlobeNewsWire • 09/28/22
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of AmericaGlobeNewsWire • 09/26/22
Windtree to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License AgreementGlobeNewsWire • 08/23/22
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 08/11/22
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder ValueGlobeNewsWire • 06/29/22
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in MadridGlobeNewsWire • 05/23/22
Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic ShockGlobeNewsWire • 05/16/22
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 05/05/22
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure ConferenceGlobeNewsWire • 04/20/22
Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic ShockGlobeNewsWire • 04/20/22
Windtree to Participate in the Lytham Partners Spring 2022 Investor ConferenceGlobeNewsWire • 03/31/22
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 03/31/22
Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory DistressBenzinga • 03/22/22
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung InjuryGlobeNewsWire • 03/22/22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic ShockGlobeNewsWire • 03/15/22